GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk (NVO) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% ...

In the latest trading session, Novo Nordisk (NVO) closed at $108.82, marking a -0.14% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.19% for the day.

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Few companies have broken into the public’s consciousness as thoroughly as Novo Nordisk has over the past couple of years. Its Wegovy weight-loss drug and Ozempic diabetes treatment are so ...

Three separate asset management firms launched exchange-traded funds on Tuesday, unveiling products focused on securitized ...